Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of AZD5863 in advanced or metastatic CLDN18.2-positive solid tumors
jRCT2031230200Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of HBM7022 and rilvegostomig in gastric cancer (GC), gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC) and 1 more (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events and dose-limiting toxicities, Adverse events leading to discontinuation and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
HBM7022rilvegostomig
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031230200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230200.